Rejuven held pre-IND meeting with FDA

Rejuven Dermaceutical held pre-IND meeting with FDA of the US on January 14, 2019. Rejuven’s RJV001 as a new BLA will seek IND approval, and its development process including CMC, non clinical and clinical studies was discussed, clarified and approved. 


Copyright © 2018 Hangzhou Rejuven Dermaceutical Co., Ltd. All Rights Reserved Zhejiang Public Network Security No. 330108020005711 Zhejiang ICP 15013641